APP and Alzheimer disease: The time- and dose-dependent response observed here with DGC-derived fraction 10 of human AD brain homogenate as well as the seemingly instant reduction of oligomers without additional pre-incubation time is very similar to the one observed in fraction 10 of APP/PS1 mouse brain homogenate before (Figure 3).